Join
Live feed
·
PRReleasevia Quantisnow
Praxis Precision Medicines Inc. logo

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

ByQuantisnow·Wall Street's wire, on your screen.
PRAX· Praxis Precision Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRAX (Praxis Precision Medicines Inc.) and more on Quantisnow.